rss
J Clin Pathol 2008;61:327-332 doi:10.1136/jcp.2007.052431
  • Original article

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis

  1. M A Thorat1,
  2. C Marchio2,3,
  3. A Morimiya1,
  4. K Savage2,
  5. H Nakshatri4,5,
  6. J S Reis-Filho2,
  7. S Badve1,6
  1. 1
    Department of Pathology and Laboratory Medicine, IU School of Medicine, Indianapolis, IN 46202, USA
  2. 2
    Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
  3. 3
    Department of Biomedical Science and Human Oncology, University of Turin, Turin, Italy
  4. 4
    Department of Surgery, IU School of Medicine, Indianapolis, IN 46202, USA
  5. 5
    Department of Biochemistry and Molecular Biology, IU School of Medicine, Indianapolis, IN 46202, USA
  6. 6
    Department of Internal Medicine, IU School of Medicine, Indianapolis, IN 46202, USA
  1. Sunil Badve, Department of Pathology, Indiana University School of Medicine, 635 Barnhill Drive, MS-A128, Indianapolis, IN 46202, USA; sbadve{at}iupui.edu
  • Accepted 4 November 2007
  • Published Online First 23 November 2007

Abstract

Aims: Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast cancer cells. It is essential for optimal expression of ~50% of oestrogen receptor (ER)-related genes. This study explored the FOXA1 relationship with luminal and basal breast cancer subtypes, proliferation markers, and survival in breast cancer patients who had received similar treatment.

Methods: A tissue microarray comprising tumours from 245 invasive breast cancer patients with 67 months of median follow-up was analysed for FOXA1 expression by immunohistochemistry. Interpretable FOXA1 expression, obtained in 184 patients, was analysed along with other variables such as tumour grade, size, nodal status, ER, progesterone receptor, HER2/neu, proliferation and basal markers.

Results: FOXA1 expression (score >3) was seen in 139 of 184 breast cancers. It correlated positively with ERα (p<0.0001), progesterone receptor (p<0.0001), and luminal subtype (p<0.0001); negatively with basal subtype (p<0.0001), proliferation markers and high histological grade (p = 0.0327). Univariate analysis showed nodal status, tumour grade, ER, progesterone receptor, FOXA1, basal markers and p53 as significant predictors of overall survival. Multivariate analysis showed that only nodal status (p = 0.0006) and ER (p = 0.0017) were significant predictors of OS. In luminal subtype patient subgroup, FOXA1 expression was associated with better survival (p = 0.0284) on univariate analysis.

Conclusion: Based on this study in patients treated with surgery followed by adjuvant anthracycline-based chemotherapy, FOXA1 expression is associated with good prognosis. It correlates with luminal subtype breast cancer, and could possibly serve as a clinical marker for luminal subtype A. Prognostic ability of FOXA1 in these low-risk breast cancers may prove to be useful in treatment decision making.

Footnotes

  • Funding: This study was funded in part by Breakthrough Breast Cancer.

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. jcp.2007.052431v1
    2. 61/3/327 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.